有研新材(600206.SH):子公司有研億金擬引入二期基金戰略投資者
格隆匯6月24日丨有研新材(600206.SH)公佈,為進一步發揮國內靶材行業領軍優勢、打造全球一流材料企業,公司全資子公司有研億金擬引入戰略投資者。有研億金以評估基準日2024年9月30日100%股權對應的淨資產值4,994,265,800.00元為基準,進行增資擴股。二期基金認繳註冊資本為人民幣50,818,280.44元,佔增資後有研億金註冊資本5.67%,二期基金投資總額為人民幣300,000,000.00元,投資總額超出註冊資本的部分249,181,719.56元計入資本公積。本次股權融資資金將全部用於集成電路領域靶材研發及靶材相關經營業務,如高純材料能力提升、粉末冶金靶材開發、加工能力提升等。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.